Key takeaway: The investor presentation from Supriya Lifescience Limited, dated August 13, 2026, provided an overview of the company's unaudited financial results for the quarter ended June 30, 2026. The presentation highlighted a 31% year-on-year increase in revenue, reaching INR 1,897.5 million, while EBITDA decreased by 8% to INR 474.6 million. The profit after tax (PAT) saw a significant decline of 30.9% year-on-year, amounting to INR 240.4 million. The document detailed the company's diversified operations across 120+ countries and emphasized its strong export presence, contributing to 81% of revenue. Management noted ongoing efforts in R&D, with plans for new product launches in anesthetics and ADHD therapies. The presentation also outlined the company's backward integration strategy, aimed at enhancing operational efficiency and margin sustainability. Overall, the document conveyed a comprehensive view of the company's performance and strategic initiatives.

Key takeaway: Supriya Lifescience Limited held its Q4 FY26 Earnings Conference Call on May 28, 2026, where management reported a significant regulatory milestone with the USFDA’s Establishment Inspection Report received for their Lote facility, indicating strong compliance. The company achieved record quarterly revenue of INR 277 crores in Q4 FY26, contributing to an 18.9% year-on-year revenue growth to INR 828 crores for FY26. Despite industry challenges, management noted resilient performance driven by a favorable product mix and disciplined cost management. The export segment accounted for 82% of revenues, with Europe showing healthy growth. Management highlighted new product launches in cardiovascular and ADHD segments, with plans for further launches in FY27. They reiterated a goal of approximately 20% annual revenue growth and an EBITDA margin of 33% to 35%. The company is also set to begin phased development of the Patalganga land in FY27, aiming for a revenue milestone of INR 1,000 crores by FY27.

Key takeaway: Supriya Lifescience Limited's investor presentation dated May 27, 2026, provided an overview of the company's audited financial results for the quarter and year ended March 31, 2026. The presentation highlighted a 50% year-on-year increase in revenue for Q4 FY26, reaching INR 2,765.3 million, and an 18.9% increase for the full fiscal year, totaling INR 8,278.7 million. EBITDA for Q4 FY26 was reported at INR 976.2 million, reflecting a 44.4% increase year-on-year. The company noted strong performance across various therapeutic areas, with significant contributions from anesthetics and anti-histamines. The presentation also detailed the company's global presence, with operations in over 120 countries and a focus on expanding its product pipeline. Management emphasized a commitment to R&D and regulatory compliance, with plans for future product launches and capacity enhancements.

Key takeaway: During the earnings call for Q3 FY26, management reported a revenue of INR 206 crores, marking an 11% year-on-year growth, driven by strong demand across their product portfolio. The EBITDA margin was reported at 34.9%, while the PAT margin stood at 24.1%. Exports contributed significantly, accounting for 82% of revenues, with the LatAm region showing notable growth. Management highlighted successful product launches, including a cardiovascular product and an ADHD product, and noted that their Ambernath facility is ready for capitalization. They reiterated a goal of approximately 20% annual revenue growth and EBITDA margins of 33% to 35%. Management expressed confidence in achieving their revenue milestone of INR 1,000 crores for FY27, supported by a healthy pipeline of planned launches and steady demand across core therapeutic segments. The call concluded with management emphasizing their focus on scaling presence in regulated markets and reinforcing competitive positioning through backward integration.

Key takeaway: Supriya Lifescience Limited's investor presentation dated February 9, 2026, provided an overview of the company's unaudited financial results for the quarter and nine months ended December 31, 2025. The presentation highlighted an 11% year-on-year increase in revenue for Q3 FY26, reaching INR 2,064.4 million, and a 7.6% increase for the nine months, totaling INR 5,513.5 million. EBITDA margins for Q3 FY26 were reported at 34.9%, slightly down from 35.5% in Q3 FY25. The company emphasized its diversified operations across 120+ countries and its strong export performance, which constituted 82% of Q3 FY26 revenue. Management noted ongoing investments in R&D and capacity enhancements, including the commissioning of a new production block, aimed at supporting future growth and product development. The presentation also detailed the company's regulatory achievements and commitment to compliance.